AMRX Stock: Price, Earnings History and SEC Filings
Amneal Pharmaceuticals, Inc. (AMRX) last traded at $21.51, up 0.75% on the latest session and up 6.8% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $0.27 against an analyst estimate of $0.24, a beat of 12.5%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
AMRX earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Jul 30, 2026 | $0.27 | $0.24 | +12.50% |
| Mar 2026 | Apr 22, 2026 | $0.26 | $0.15 | +73.33% |
| Dec 2025 | Feb 27, 2026 | $0.19 | $0.17 | +11.76% |
| Sep 2025 | Oct 30, 2025 | $0.15 | $0.12 | +25.00% |
AMRX beat the analyst EPS estimate in 4 of its last 4 reported quarters. Source: Nasdaq.
How AMRX reacts to earnings
Across its last 8 earnings releases, AMRX moved 2.5% on average the next session, in either direction. It rose after 1 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-07-30 | Before open | -3.14% |
| 2026-05-07 | After close | -3.79% |
| 2026-04-22 | Before open | -1.54% |
| 2026-02-27 | Before open | -4.69% |
| 2026-01-13 | Before open | -0.08% |
| 2025-10-30 | Before open | -4.12% |
| 2025-08-05 | Before open | +2.14% |
| 2025-07-21 | Before open | -0.75% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
AMRX financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $3.0B | $72M | $270M | 2.4% | $0.22 |
| 2024 | $2.8B | -$117M | $243M | -4.2% | $-0.38 |
| 2023 | $2.4B | -$84M | $302M | -3.5% | $-0.48 |
| 2022 | $2.2B | -$271M | $19M | -12.2% | $-0.86 |
| 2021 | $2.1B | $13M | $194M | 0.6% | $0.07 |
| 2020 | $2.0B | $68M | $323M | 3.4% | $0.61 |
| 2019 | $1.6B | -$604M | -$45M | -37.1% | $-2.74 |
| 2018 | $1.7B | -$20M | $167M | -1.2% | $-0.16 |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for AMRX
- 8-K · Aug 10, 2026Material agreement, Acquisition or disposal completed, New financial obligation
- 10-Q · Aug 6, 2026
- 8-K · Aug 3, 2026Material agreement
- 8-K · Jul 31, 2026Shareholder vote
- 8-K · Jul 30, 2026Results of operations, Regulation FD disclosure, Financial statements and exhibits
- 10-Q · May 7, 2026
- 8-K · May 7, 2026Shareholder vote
- 8-K · May 7, 2026Results of operations, Financial statements and exhibits
- 8-K · Apr 22, 2026Material agreement, Results of operations, Unregistered share sale
- DEF 14A · Mar 25, 2026
Insider filing activity
AMRX insiders filed 12 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
AMRX news
- GILD Beats Q3 Earnings on HIV Strength & Trodelvy Sales GrowthOct 30, 2026 · finance.yahoo.com
- INSM Q3 Earnings Miss, Stock Soars on Sales Beat & Raised GuidanceOct 30, 2026 · finance.yahoo.com
- HALO Gears Up to Report Q3 Earnings: Is a Beat in the Cards?Oct 30, 2026 · finance.yahoo.com
- VKTX Q3 Earnings Miss Estimates Amid Rising Clinical ExpensesOct 29, 2026 · finance.yahoo.com
- Amarin's Q3 Earnings Beat Estimates, Revenues Miss MarkOct 29, 2026 · finance.yahoo.com
- BHC Q3 Earnings Beat on Salix Growth, Stock Gains 9% as Outlook RisesOct 29, 2026 · finance.yahoo.com
- Indivior Pharmaceuticals Inc. (INDV) Beats Q3 Earnings and Revenue EstimatesOct 29, 2026 · finance.yahoo.com
- Where Does Amneal Pharmaceuticals (AMRX) Value Sit After A 4.4x Run?Oct 29, 2026 · finance.yahoo.com
About Amneal Pharmaceuticals, Inc.
Amneal Pharmaceuticals, Inc. (AMRX) is a US-listed public company on Nasdaq. The SEC classifies its business as Pharmaceutical Preparations. Its fiscal year ends in December.